Growth Hormone Secretagogues Compared: Best GHS Peptides in 2026

Growth hormone secretagogues (GHS) are among the most researched peptide compounds in modern sports science and longevity medicine. Whether you're evaluating them for body composition, recovery acceleration, or anti-aging protocols, the differences between each compound matter enormously. This guide compares the top GHS peptides head-to-head so you can understand what the research actually says before making any decision.

What Are Growth Hormone Secretagogues?

Growth hormone secretagogues are compounds — peptide and non-peptide alike — that stimulate the pituitary gland to release endogenous growth hormone (GH). Unlike exogenous HGH injections, GHS compounds work by triggering your body's own GH-secreting machinery, which is why researchers consider them a more physiologically nuanced approach.

There are two primary receptor pathways through which GHS compounds operate:

• GHRH receptor agonists — mimic or enhance the action of growth hormone releasing hormone (e.g., Sermorelin, CJC-1295)
• Ghrelin receptor agonists (GHSR) — bind the ghrelin receptor to trigger GH release (e.g., Ipamorelin, GHRP-2, GHRP-6, MK-677)

Stacking one compound from each category is a widely studied strategy to produce synergistic GH pulses that more closely mimic natural, youthful GH secretion patterns. Understanding how each compound differs mechanistically is the foundation for comparing them rationally.

Ipamorelin vs CJC-1295: The Classic Stack

Ipamorelin and CJC-1295 are consistently the most discussed GHS combination in research literature, and for good reason. They operate on complementary pathways, producing a powerful synergistic effect when combined.

Ipamorelin

Ipamorelin is a selective GHSR agonist and a pentapeptide. It stands out from other GHRPs (growth hormone releasing peptides) because of its high selectivity — it stimulates GH release with minimal impact on cortisol, prolactin, or ACTH levels. This selective profile makes it the preferred introductory GHS for researchers evaluating tolerability.

• Mechanism: Ghrelin receptor agonist
• GH pulse strength: Moderate-to-strong
• Cortisol impact: Minimal
• Half-life: ~2 hours
• Best use case: Clean GH stimulation, anti-aging, body recomposition

CJC-1295

CJC-1295 (with DAC — Drug Affinity Complex) is a modified GHRH analogue with an extended half-life of 6–8 days, achieved by its ability to bind albumin in the bloodstream. This creates a sustained "GH bleed" effect rather than discrete pulses. The DAC version is distinguished from Modified GRF (1-29), also called CJC-1295 without DAC, which has a shorter half-life and produces more physiological pulse patterns.

• Mechanism: GHRH receptor agonist
• GH pulse strength: Strong sustained elevation
• Cortisol impact: Minimal
• Half-life: 6–8 days (with DAC)
• Best use case: Sustained IGF-1 elevation, combined stack protocols

GHRP-2 vs GHRP-6: Potency vs Hunger

GHRP-2 and GHRP-6 are first-generation GHRPs that preceded Ipamorelin. Both are hexapeptides that bind the ghrelin receptor, but they differ in their side effect profiles in ways that matter practically.

GHRP-2

GHRP-2 is considered the more potent of the two, producing robust GH pulses. However, it does elevate cortisol and prolactin to a greater degree than Ipamorelin, making it less ideal for long-duration research protocols where HPA axis disruption is a concern.

• GH pulse strength: High
• Cortisol/Prolactin elevation: Moderate
• Hunger stimulation: Moderate
• Half-life: ~1 hour

GHRP-6

GHRP-6 was one of the earliest synthetic GHRPs studied. It produces strong GH release but is notorious for significantly increasing appetite — a direct consequence of its ghrelin receptor activity. This hunger effect may be useful in research contexts examining cachexia or underfeeding, but is often considered undesirable for body composition studies.

• GH pulse strength: High
• Cortisol/Prolactin elevation: Moderate-to-high
• Hunger stimulation: Very high
• Half-life: ~1–2 hours

Sermorelin: The Physiological GHRH Analogue

Sermorelin is the synthetic analogue of the first 29 amino acids of endogenous GHRH (GHRH 1-29). It was FDA-approved for pediatric growth hormone deficiency and has the most established clinical safety record of any GHS compound discussed here.

Unlike CJC-1295 with DAC, Sermorelin has a very short half-life (10–20 minutes), producing discrete GH pulses that closely mimic the body's natural ultradian rhythm. Researchers studying GH axis restoration — particularly in aging populations — often consider Sermorelin the most physiologically appropriate choice.

• Mechanism: GHRH receptor agonist (GHRH 1-29)
• Half-life: 10–20 minutes
• Clinical history: Former FDA approval (pediatric GHD)
• Best use case: Anti-aging, HPA-axis normalization, conservative GH augmentation

Sermorelin is often stacked with Ipamorelin for a physiologically conservative synergistic protocol. Because it lacks the DAC modification, it requires more frequent dosing than CJC-1295 with DAC but avoids the sustained elevated IGF-1 that some researchers flag as a concern with longer-acting analogues.

MK-677: The Oral Non-Peptide GHS

MK-677 (Ibutamoren) is fundamentally different from the peptides above. It is a non-peptide, orally bioavailable ghrelin mimetic — the only GHS in this comparison that does not require subcutaneous injection. Originally developed by Merck, it was studied in clinical trials for muscle wasting, obesity, and osteoporosis.

MK-677 produces sustained, 24-hour elevations in GH and IGF-1 rather than discrete pulses. This makes it pharmacologically distinct — and the sustained IGF-1 elevation is both its primary appeal and the subject of ongoing research scrutiny.

The convenience of oral administration makes MK-677 widely studied in populations where injection compliance is a concern. However, its non-pulsatile GH elevation pattern diverges from physiological norms, and researchers have noted potential for insulin resistance with long-term use — a consideration not seen with shorter-acting injectable GHS compounds.

Which GHS Is Right for the Research Goal?

Choosing between growth hormone secretagogues requires matching the compound's pharmacological profile to the specific research objective. Here's how the leading options stratify by use case:

• Muscle hypertrophy and body recomposition: CJC-1295 + Ipamorelin stack or MK-677 for sustained IGF-1 elevation
• Recovery and injury repair: Ipamorelin + CJC-1295; consider stacking with BPC-157 or TB-500 for synergistic tissue repair signaling
• Anti-aging / longevity protocols: Sermorelin for physiological GH pulse restoration; MK-677 for long-term IGF-1 support
• Minimal side effect profile: Ipamorelin alone or Sermorelin — both demonstrate the cleanest endocrine selectivity
• Injection-averse research subjects: MK-677 is the only oral option
• Appetite stimulation (cachexia research): GHRP-6 produces the strongest orexigenic effect

Frequently Asked Questions